These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1130 related articles for article (PubMed ID: 28302645)
1. PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. Juneja VR; McGuire KA; Manguso RT; LaFleur MW; Collins N; Haining WN; Freeman GJ; Sharpe AH J Exp Med; 2017 Apr; 214(4):895-904. PubMed ID: 28302645 [TBL] [Abstract][Full Text] [Related]
2. Newly emerged immunogenic neoantigens in established tumors enable hosts to regain immunosurveillance in a T-cell-dependent manner. Muramatsu T; Noguchi T; Sugiyama D; Kanada Y; Fujimaki K; Ito S; Gotoh M; Nishikawa H Int Immunol; 2021 Jan; 33(1):39-48. PubMed ID: 32729901 [TBL] [Abstract][Full Text] [Related]
4. CD4 Xiao M; Xie L; Cao G; Lei S; Wang P; Wei Z; Luo Y; Fang J; Yang X; Huang Q; Xu L; Guo J; Wen S; Wang Z; Wu Q; Tang J; Wang L; Chen X; Chen C; Zhang Y; Yao W; Ye J; He R; Huang J; Ye L J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580929 [TBL] [Abstract][Full Text] [Related]
5. The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1. Sugita Y; Furuta T; Ohshima K; Komaki S; Miyoshi J; Morioka M; Abe H; Nozawa T; Fujii Y; Takahashi H; Kakita A Neuropathology; 2018 Apr; 38(2):125-134. PubMed ID: 29067721 [TBL] [Abstract][Full Text] [Related]
6. Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine. Kim H; Khanna V; Kucaba TA; Zhang W; Ferguson DM; Griffith TS; Panyam J Mol Pharm; 2019 Mar; 16(3):1200-1210. PubMed ID: 30620878 [TBL] [Abstract][Full Text] [Related]
7. Antitumor Effect of Korean Red Ginseng through Blockade of PD-1/PD-L1 Interaction in a Humanized PD-L1 Knock-In MC38 Cancer Mouse Model. Lee EJ; Yang JH; Yang HJ; Cho CK; Choi JG; Chung HS Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768213 [TBL] [Abstract][Full Text] [Related]
8. Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses. Liu B; Guo H; Xu J; Qin T; Guo Q; Gu N; Zhang D; Qian W; Dai J; Hou S; Wang H; Guo Y MAbs; 2018; 10(2):315-324. PubMed ID: 29182441 [TBL] [Abstract][Full Text] [Related]
9. B16 melanoma control by anti-PD-L1 requires CD8+ T cells and NK cells: application of anti-PD-L1 Abs and Trp2 peptide vaccines. Ji S; Lee J; Lee ES; Kim DH; Sin JI Hum Vaccin Immunother; 2021 Jul; 17(7):1910-1922. PubMed ID: 33522416 [TBL] [Abstract][Full Text] [Related]
10. SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA. Wu R; Wang C; Li Z; Xiao J; Li C; Wang X; Kong P; Cao J; Huang F; Li Z; Huang Y; Chen Y; Li X; Yang D; Zhang H; Mai J; Feng G; Deng R; Zhu X J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33158915 [TBL] [Abstract][Full Text] [Related]
12. Frontline Science: Defects in immune function in patients with sepsis are associated with PD-1 or PD-L1 expression and can be restored by antibodies targeting PD-1 or PD-L1. Patera AC; Drewry AM; Chang K; Beiter ER; Osborne D; Hotchkiss RS J Leukoc Biol; 2016 Dec; 100(6):1239-1254. PubMed ID: 27671246 [TBL] [Abstract][Full Text] [Related]
13. Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells. Homet Moreno B; Zaretsky JM; Garcia-Diaz A; Tsoi J; Parisi G; Robert L; Meeth K; Ndoye A; Bosenberg M; Weeraratna AT; Graeber TG; Comin-Anduix B; Hu-Lieskovan S; Ribas A Cancer Immunol Res; 2016 Oct; 4(10):845-857. PubMed ID: 27589875 [TBL] [Abstract][Full Text] [Related]
14. Targeting the YB-1/PD-L1 Axis to Enhance Chemotherapy and Antitumor Immunity. Tao Z; Ruan H; Sun L; Kuang D; Song Y; Wang Q; Wang T; Hao Y; Chen K Cancer Immunol Res; 2019 Jul; 7(7):1135-1147. PubMed ID: 31113805 [TBL] [Abstract][Full Text] [Related]
15. Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape. Noguchi T; Ward JP; Gubin MM; Arthur CD; Lee SH; Hundal J; Selby MJ; Graziano RF; Mardis ER; Korman AJ; Schreiber RD Cancer Immunol Res; 2017 Feb; 5(2):106-117. PubMed ID: 28073774 [TBL] [Abstract][Full Text] [Related]
16. Augmented Antitumor Effect of Unripe Lee EJ; Yang JH; Choi JG; Chung HS Cells; 2022 Sep; 11(18):. PubMed ID: 36139451 [TBL] [Abstract][Full Text] [Related]
17. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer. Guo Z; Wang H; Meng F; Li J; Zhang S J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551 [TBL] [Abstract][Full Text] [Related]
18. A soluble form of CD80 enhances antitumor immunity by neutralizing programmed death ligand-1 and simultaneously providing costimulation. Haile ST; Horn LA; Ostrand-Rosenberg S Cancer Immunol Res; 2014 Jul; 2(7):610-5. PubMed ID: 24819296 [TBL] [Abstract][Full Text] [Related]
19. An Immunomodulatory Gallotanin-Rich Fraction From Lasso P; Gomez-Cadena A; UrueƱa C; Donda A; Martinez-Usatorre A; Romero P; Barreto A; Fiorentino S Front Immunol; 2020; 11():584959. PubMed ID: 33312174 [TBL] [Abstract][Full Text] [Related]
20. YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma. Kim MH; Kim CG; Kim SK; Shin SJ; Choe EA; Park SH; Shin EC; Kim J Cancer Immunol Res; 2018 Mar; 6(3):255-266. PubMed ID: 29382670 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]